The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.
To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.
Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.
To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.
To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.
To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.
To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.
As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.
To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.
Policy makers may be better able to evaluate the progress of measles elimination and rubella control programs by understanding population immunity through large-scale serological surveys. This is a collaborative study led by the Indian Council of Medical Research.
Read More >
The Immunization Reminder and Information SMS System (IRISS) is a demand creation intervention that will be implemented by IVAC in Nigeria in collaboration with the Direct Consulting and Logistics (DCL) Limited.
Read More >
The study will elucidate the novel problem of missed opportunities during hospitalization by quantifying the proportion of under-vaccinated children who remain unvaccinated at the time of hospital discharge. Our study is designed to systematically collect the vaccination status of hospitalized children at the time of admission and discharge, while also documenting caregivers’ and healthcare providers’ perspectives on barriers to vaccine access.
Read More >
MOMENTUM Country and Global Leadership program (MCGL-USAID): Contributing to sustainably reducing maternal, newborn, and child mortality and morbidity, and mitigating the impact of the COVID-19 pandemic. Are you engaged in executing a learning agenda on immunization systems disruption and resilience in the context of COVID-19? Take a short survey here Assessing routine immunization in the […]
Read More >
This study will establish and maintain a surveillance network to measure the impact of routine infant vaccination with PCV on serotypes causing invasive pneumococcal disease among young children under 5 years of age in India.
Read More >